Hill, Replimune CFO, sells $49k in REPL stock
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Replimune Group Inc (REPL)
Replimune Group Inc stock price live, this page displays NASDAQ REPL stock exchange data. View the REPL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Replimune Group Inc real time stock price chart below.
What Is the Replimune Group Inc Stock Price Today?
The Replimune Group Inc stock price today is 5.40.
What Is the Stock Symbol for Replimune Group Inc?
The stock symbol for Replimune Group Inc is ""REPL.""
What Stock Exchange Does Replimune Group Inc Trade On?
Replimune Group Inc is listed and trades on the NASDAQ stock exchange.
Is Replimune Group Inc a Good Stock to Buy?
Determining whether Replimune Group Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the REPL quote. (ISIN: US76029N1063)
What Is the Replimune Group Inc Stock Price Today?
The Replimune Group Inc stock price today is 5.40.
What Is the Stock Symbol for Replimune Group Inc?
The stock symbol for Replimune Group Inc is ""REPL.""
What Stock Exchange Does Replimune Group Inc Trade On?
Replimune Group Inc is listed and trades on the NASDAQ stock exchange.
Is Replimune Group Inc a Good Stock to Buy?
Determining whether Replimune Group Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the REPL quote. (ISIN: US76029N1063)
Fair Value
An estimate of a Replimune's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.33
5.54
52 wk Range
2.68
17.00
REPL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
REPL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Replimune's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.335.54
52 wk Range
2.6817.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
REPL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Replimune's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
4.86
Downside
-10.05%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Replimune Group Inc Company Profile
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group Inc SWOT Analysis
FDA Setback Impact | Explore how Replimune's regulatory challenges with RP1 have affected its market position and future prospects in the competitive oncology landscape |
Financial Outlook | Delve into Replimune's financial health, including its cash reserves, burn rate, and projected earnings, amid ongoing clinical trials and regulatory hurdles |
Pipeline Potential | Uncover the diverse applications of Replimune's RP1 treatment beyond melanoma, including skin cancers and organ transplants, driving future growth |
Industry Dynamics | Analyst targets range from $2 to $9 with a consensus HOLD rating, reflecting the biotech sector's positive outlook despite Replimune's current challenges |
Replimune Group Inc Earnings Call Summary for Q4/2025
- Replimune reported Q1 2025 EPS of -$3.07, missing -$0.72 forecast; stock dropped 7.94% but showed 2.13% premarket recovery
- Cash and equivalents rose to $483.8M, extending runway to Q4 2026; R&D expenses $54M for Q4, $189.4M for fiscal year
- RP-one received breakthrough therapy designation; PDUFA date set for July 2025; 60-person commercial team established
- CEO confident in RP-one's market potential; company preparing for June 2025 Investor Day and ASCO conference presentation
- Challenges include earnings miss scrutiny, competitive landscape, and rising operational costs for commercial infrastructure
Last Updated: 22/05/2025, 13:58
Read Full TranscriptCompare REPL to Peers and Sector
Metrics to compare | REPL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipREPLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | −3.0x | −0.5x | |
PEG Ratio | 0.13 | 0.02 | 0.00 | |
Price/Book | 1.3x | 2.2x | 2.6x | |
Price / LTM Sales | - | 8.7x | 3.2x | |
Upside (Analyst Target) | −25.9% | 176.2% | 37.1% | |
Fair Value Upside | Unlock | −3.1% | 5.4% | Unlock |
Analyst Ratings
2 Buy
6 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 4.86
(-10.05% Downside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-0.95 / -0.8429
Revenue / Forecast
-- / 1.98M
People Also Watch
FAQ
What Stock Exchange Does Replimune Trade On?
Replimune is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Replimune?
The stock symbol for Replimune is "REPL."
What Is the Replimune Market Cap?
As of today, Replimune market cap is 421.50M.
What Is Replimune's Earnings Per Share (TTM)?
The Replimune EPS (TTM) is -3.60.
When Is the Next Replimune Earnings Date?
Replimune will release its next earnings report on 17 Nov 2025.
From a Technical Analysis Perspective, Is REPL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Replimune Stock Split?
Replimune has split 0 times.
How Many Employees Does Replimune Have?
Replimune has 479 employees.
What is the current trading status of Replimune (REPL)?
As of 01 Sept 2025, Replimune (REPL) is trading at a price of 5.40, with a previous close of 5.38. The stock has fluctuated within a day range of 5.33 to 5.54, while its 52-week range spans from 2.68 to 17.00.
What Is Replimune (REPL) Price Target According to Analysts?
The average 12-month price target for Replimune is USD4.85714, with a high estimate of USD8 and a low estimate of USD2. 2 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an -10.05% Downside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.